Nuwellis shares are trading higher after the company announced the first pediatric patient was treated in a commercial setting with SeaStar Medical's QUELIMMUN therapy.
Portfolio Pulse from Benzinga Newsdesk
Nuwellis shares are trading higher after the company announced the first pediatric patient was treated in a commercial setting with SeaStar Medical's QUELIMMUN therapy.
July 29, 2024 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nuwellis shares are trading higher following the announcement that the first pediatric patient was treated in a commercial setting with SeaStar Medical's QUELIMMUN therapy.
The news indicates a significant milestone for Nuwellis, showcasing the practical application and commercial potential of SeaStar Medical's QUELIMMUN therapy. This positive development is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100